Story thread · 2 reports / 2 sources

AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint

investing.com · 4h · first report

The coverage

  1. AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

    seekingalpha.com · 3h

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.